Overview
Fasting glucose tells you the result. Fasting insulin tells you what it cost to get there. Two people can have an identical, entirely normal fasting glucose while one is producing far more insulin to hold it there — and that difference tends to appear years before the glucose number ever moves.
Which is why insulin is one of the most useful markers on a panel and one of the least often ordered.
| What is measured | What it shows | When it changes |
|---|---|---|
| Fasting glucose | The outcome — how much sugar is in your blood | Late. Often normal for years while compensation is happening |
| HbA1c | Average glucose over roughly three months | Also relatively late, and affected by red cell turnover |
| Fasting insulin | The effort required to hold glucose steady | Early. Often rises well before glucose does |
| HOMA-IR | Glucose and insulin combined into one index | Early, and easier to track over time than either alone |
The practical point: a normal fasting glucose alongside a high fasting insulin is a meaningfully different situation from a normal glucose alongside a low-normal insulin, and only one of the two panels will show you which you are.
What insulin is doing
Insulin's main job is to move glucose out of the bloodstream and into cells. When cells respond less readily to it — insulin resistance — the pancreas compensates by producing more. For a long time that compensation works: glucose stays normal because insulin is doing more work to keep it there.
That period of successful compensation is where a great many people in midlife are sitting, and it is invisible on a standard panel. Glucose looks fine. HbA1c looks fine. The person is told their blood sugar is normal, which is true and not the whole story.
Only when the pancreas can no longer keep pace does glucose start to drift. By then the process has usually been running for years.
Where the ranges sit
Most laboratories report fasting insulin reference ranges of roughly 2–25 µIU/mL, with substantial variation between laboratories and assays.
That upper bound deserves comment, because it is unusually wide. Reference ranges describe the middle of a population, and in a population where insulin resistance is common the range shifts with it — a value can be "within range" and still reflect meaningful compensation. Many clinicians working in metabolic health therefore look at fasting insulin against a tighter working range than the laboratory prints, while being clear that this is interpretive judgment rather than a diagnostic threshold.
We would rather say that openly than present a specific number as though it were settled. What the value means depends on your glucose, your waist, your lipids and your history — not on where it falls in a printed range.
Two practical caveats: the sample must genuinely be fasting, ideally 8–12 hours, and insulin assays vary enough between laboratories that results are not directly comparable. Track it at the same lab if you are tracking it at all.
Why it matters before glucose does
The reason to look early is that this stage is the most modifiable.
Insulin sensitivity responds well to the things that are hardest to sell and most reliable to do: resistance training, which increases the muscle available to take up glucose; regular movement, particularly after meals; adequate sleep, since even short-term sleep restriction measurably reduces insulin sensitivity; reduced alcohol; and losing visceral fat specifically, which is more responsive than total weight.
None of that is novel. What is useful is knowing whether it applies to you, and having a number that shows whether it is working — because insulin will move before glucose does in that direction too.
Reading it alongside everything else
Fasting insulin is not a standalone test. Read together with glucose it produces HOMA-IR, which is more informative than either value alone and easier to follow over time. How that works.
Read alongside a lipid panel it becomes more informative again. Insulin resistance has a recognizable signature: raised triglycerides, low HDL, and a waist that has grown even when total weight has not moved much. Seeing those together is more persuasive than any single result.
And read alongside SHBG, it gets interesting for a different reason. Low SHBG frequently accompanies insulin resistance, which is why a hormone panel sometimes flags a metabolic issue before the metabolic panel does. What SHBG is doing there.
What a high result is not
It is not a diagnosis of diabetes, and it is not prediabetes — both of those are defined on glucose criteria, not insulin.
It is not a reason for medication on its own. Whether anything pharmacological is appropriate is a clinical decision made on the whole picture, and in most people at this stage the lever with the best evidence behind it is training and body composition rather than a prescription.
And it is not a number to chase in isolation. The point of measuring it is to know which direction you are heading, early enough that direction is still easy to change.
Frequently asked questions
Why does my doctor only check glucose? Fasting glucose and HbA1c are the guideline tests for diagnosing diabetes and prediabetes, and they do that job well. Fasting insulin is not a diagnostic criterion, which is why it is not routine — it is used to see earlier, not to diagnose.
Can fasting insulin be too low? A low fasting insulin in someone with normal glucose generally reflects good insulin sensitivity. Genuinely inadequate insulin production is a different clinical situation and comes with abnormal glucose.
How often is it worth repeating? Not often. It is a marker that moves over months, so annually, or after a genuine change in training, weight or sleep, is more useful than frequent repeats.
Does this replace an HbA1c? No. They answer different questions — HbA1c is the average outcome, insulin is the effort. A panel that has both tells you more than either alone.
Where this fits in your plan
Fasting insulin is the marker that tends to move first, which makes it the one worth having if you want to know where you are heading rather than where you have arrived.
It belongs on a panel alongside glucose, HbA1c, a full lipid picture and — because they turn out to be connected — your hormone results. That is what a comprehensive panel is for.
We measure first. Then we act.
Diagnostic testing does not diagnose or rule out disease on its own and is interpreted by a licensed provider alongside your history and examination.
Ready to start your second act?
It starts with measuring, not guessing. A short, clinician-reviewed assessment shows what fits you.
This article is educational and is not medical advice. Treatments are available only to eligible patients following clinical evaluation and within applicable regulations. Individual results vary.
